On May 23, 2026, CTV News reported on what Canadian physicians are calling an overwhelming surge of online disinformation about menopause and perimenopause. Dr. Ilana Lega, an endocrinologist at Women’s College Hospital in Toronto, told the reporter that her patients arrive with reams of social-media-sourced information that is often unreliable, sometimes harmful, and increasingly difficult to displace once it has taken hold. The article identified the weight-loss product industry as particularly aggressive in marketing to perimenopausal and menopausal women, and it noted that some patients now place more trust in their online sources than in evidence-based medical advice.
The article is a snapshot of a real and serious problem. The reporting is well-founded. The medical expert quoted is credible. The phenomenon described is consistent with what physicians across the province have been describing in clinical practice and in published commentary.
For families thinking about whether something has gone wrong with menopause-related care, however, the analytical questions are more specific. When does the information environment that the article describes lead to actual patient harm? When does that harm cross from a difficult clinical situation into something that could be the subject of a civil claim? What is the framework for evaluating menopause-related care against the standard of care, and how does it interact with the broader framework of informed consent that the law applies to all medical decisions?
This post addresses those questions. It is written for patients and families navigating the aftermath of menopause-related care that has not gone well, and for clinicians thinking about how the framework applies to the conditions in which they actually practise. It is not medical advice; decisions about specific treatments belong with the patient and their physician. It is also not legal advice; cases turn on their specific facts. It is intended as a foundational reference for understanding the framework that applies.
The information environment patients are navigating
A brief overview of the information environment is useful for the analysis.
The pre-2002 framework. Before 2002, hormone therapy (then commonly referred to as hormone replacement therapy or HRT) was widely prescribed in North America for menopausal symptoms. The framework treated hormone therapy as routine for many menopausal patients, with the understanding that it addressed vasomotor symptoms (hot flashes; night sweats) and offered protection against bone loss and possibly cardiovascular disease.
The 2002 Women’s Health Initiative inflection point. In 2002, the Women’s Health Initiative (WHI) published initial findings from a major randomized controlled trial that, on first reading, suggested hormone therapy increased the risk of breast cancer, cardiovascular events, and stroke. The framework for prescribing hormone therapy contracted dramatically. Many physicians stopped prescribing entirely. Many patients stopped taking hormone therapy. The framework’s emphasis shifted to non-hormonal approaches and to the perception that hormone therapy was generally unsafe.
The post-2002 reassessment. In the years since the initial WHI publication, subsequent analyses and additional research have produced a more calibrated framework. The current framework recognizes that:
- The initial WHI results were significantly affected by the average age of the participants (many years past menopause), the formulations used (conjugated equine estrogens with medroxyprogesterone acetate), and the absolute versus relative risk presentation
- For most women within ten years of menopause onset, hormone therapy has a more favorable risk-benefit profile than the initial framework suggested
- The framework distinguishes between formulations, doses, routes of administration, and patient-specific factors that affect the risk-benefit calculation
- Untreated severe menopausal symptoms carry their own morbidity, including impacts on sleep, mood, cognitive function, bone density, and quality of life
The framework remains contested in some respects and continues to evolve. Different professional bodies, including the North American Menopause Society and the Canadian Menopause Society, have published updated guidance reflecting the post-2002 reassessment. Where I describe the framework below, it is the framework as currently articulated in the relevant professional guidance, recognizing that medical evidence and clinical practice continue to develop.
The systematic undertreatment problem. One consequence of the post-2002 framework was systematic undertreatment of women who were good candidates for hormone therapy. The framework’s contraction left a generation of women without effective management of severe vasomotor symptoms and without the bone protection that hormone therapy can provide. The framework’s evolution since has not fully closed the gap; some physicians remain hesitant to prescribe hormone therapy even where the current evidence-based framework supports it. The framework’s lag between updated evidence and updated clinical practice is part of the problem.
The online information explosion. Beginning approximately in the early 2020s, online information about menopause and perimenopause expanded dramatically. The framework now includes legitimate educational content from physician-experts, patient advocacy organizations, and credentialed practitioners, alongside misinformation, marketing for products that may or may not be effective, and frank scams. The CTV News article captured the practical experience: women are seeking information, often appropriately, but the information environment is difficult to navigate even for sophisticated patients.
The framework’s two failure modes. From a clinical and medical-legal perspective, the current information environment supports two distinct failure modes:
- Undertreatment failure mode. A patient with significant menopausal symptoms and an appropriate clinical profile for hormone therapy does not receive it. The framework’s reasons may include physician hesitation reflecting the pre-reassessment framework, patient fear of breast cancer based on outdated information, or failure to discuss hormone therapy as one of several options. The framework’s consequence can include preventable harm to bone density, cardiovascular health, sleep, mood, and quality of life.
- Overtreatment failure mode. A patient is prescribed hormone therapy or related products in circumstances where the framework does not support them, or in formulations and doses that have not been validated, often through “wellness clinics” or compounding pharmacies operating outside the conventional medical regulatory framework. The framework’s consequence can include preventable harm to the specific patient and broader consequences for the patient’s trust in evidence-based care.
Both failure modes can give rise to malpractice claims in appropriate circumstances. The framework for evaluating each is the same: standard of care, causation, and damages. The specific application differs.
The standard of care framework for menopause-related care
The standard of care in medical malpractice litigation in Ontario is what a reasonable specialist in the same field would have done in the same circumstances, supported by expert evidence. The framework for menopause-related care operates in this general framework with several specific considerations.
The diagnostic framework. Menopause is a clinical diagnosis based on the patient’s history of menstrual cessation (typically twelve consecutive months without menses), supported where appropriate by symptom assessment and, in some cases, hormonal testing. Perimenopause is more diagnostically heterogeneous and may be diagnosed based on the constellation of clinical features, the timing in the patient’s life, and the exclusion of other causes. The framework treats both diagnoses as primarily clinical with selective use of laboratory testing.
The clinical assessment framework. Where a patient presents with menopausal or perimenopausal symptoms, the framework includes:
- Detailed symptom history including vasomotor symptoms, sleep, mood, cognitive concerns, urogenital symptoms, and sexual function
- Past medical history including breast cancer history, cardiovascular history, thromboembolic history, liver disease, and other conditions affecting treatment options
- Family history affecting the framework
- Current medications and supplements
- Risk factor assessment for cardiovascular disease, osteoporosis, breast cancer, and other conditions that interact with the framework
- Physical examination as appropriate
- Selective laboratory testing including, in appropriate cases, hormonal panels, lipid profiles, bone density studies, and other testing calibrated to the clinical picture
The treatment framework. The current framework for menopause-related treatment includes:
- Lifestyle interventions including exercise, sleep hygiene, dietary modifications, and stress management
- Non-hormonal pharmacological options for specific symptoms (SSRIs and SNRIs for vasomotor symptoms in appropriate patients; gabapentin; clonidine; selective newer agents including neurokinin-receptor antagonists)
- Hormone therapy where appropriate, with selection of formulation, dose, and route of administration calibrated to the patient’s clinical picture and preferences
- Specific framework for genitourinary symptoms including topical estrogen preparations with different risk profiles from systemic therapy
- Bone health framework including non-hormonal options where appropriate
- Cardiovascular risk management
- Mental health support as appropriate
The framework is highly individualized. The framework recognizes that the same patient population includes individuals for whom hormone therapy is the best option, individuals for whom non-hormonal pharmacotherapy is preferable, and individuals for whom lifestyle intervention alone is appropriate.
The shared decision-making framework. The framework for menopause-related care emphasizes shared decision-making. The framework requires:
- Discussion of the patient’s specific clinical picture and goals
- Discussion of the available options with their respective risks and benefits
- Discussion of the framework’s uncertainty including where the evidence is contested or evolving
- Patient input on values and preferences affecting the decision
- Documentation of the discussion and the resulting plan
The framework is not consistent with a “one-size-fits-all” approach. The framework is not consistent with dismissing patient questions or concerns. The framework is not consistent with prescribing without individualized assessment. Where a physician’s approach falls below the framework, the standard of care analysis can support a claim.
The framework for engaging with patient-sourced information. A specific subset of the framework addresses the situation the CTV News article describes: patients arriving with information sourced from online platforms that may or may not be reliable. The framework supports respectful engagement with the information the patient has found. Specifically:
- The framework recognizes that patient education is generally beneficial, even where the specific information is unreliable
- The framework treats the patient’s research as part of the clinical conversation rather than as a threat to it
- The framework supports specific discussion of why particular information is or is not reliable, with reference to the underlying evidence
- The framework supports the patient’s autonomy in decision-making even where the patient holds views the physician disagrees with
- The framework treats dismissive or condescending responses to patient research as inconsistent with the professional standards for the therapeutic relationship
Where a physician’s approach to patient-sourced information falls into dismissiveness or condescension, the framework for the therapeutic relationship is compromised. Dr. Lega’s observation captured in the CTV News article (“they don’t really trust you anymore”) describes the practical consequence: the patient leaves with their misinformation intact and the physician’s evidence-based input rejected. The framework treats this as a clinical failure that contributes to subsequent harm.
The informed consent framework
The informed consent framework operates alongside the standard of care framework for treatment-related malpractice analysis. The foundational Canadian authority is Reibl v Hughes, [1980] 2 SCR 880, which established that informed consent in Canadian medical law requires:
- Disclosure of the nature and purpose of the proposed treatment
- Disclosure of the material risks of the proposed treatment
- Disclosure of the available alternatives, including the alternative of no treatment
- Disclosure of the risks of the alternatives, including the risks of not treating
- The disclosure must be calibrated to what a reasonable patient in the position of the specific patient would want to know
For menopause-related care, the informed consent framework engages on multiple dimensions:
Material risks of hormone therapy. Where hormone therapy is offered, the framework requires disclosure of material risks including the contested but real risks identified in the WHI and subsequent literature (breast cancer, cardiovascular events, thromboembolic events, stroke, and others depending on the formulation and patient profile). The framework requires that the disclosure be accurate to the current evidence rather than to outdated framings of the risk profile.
Material risks of NOT treating. Critically, the informed consent framework also requires disclosure of the risks of not treating. For severe menopausal symptoms, the risks of not treating include impact on sleep, mood, cognitive function, bone density, cardiovascular health (in some framings), and quality of life. The framework does not permit one-sided disclosure that emphasizes treatment risks while minimizing the consequences of leaving the condition untreated.
Material risks of non-hormonal alternatives. Where non-hormonal alternatives are offered, the framework requires disclosure of their efficacy profiles (typically lower than hormone therapy for vasomotor symptoms) and their specific risks.
The framework’s application where patient comes in with online misinformation. Where a patient has been exposed to online information that may distort their understanding of the risk-benefit calculation, the informed consent framework requires the physician to engage substantively with the actual evidence base. The framework does not permit the physician to defer to the patient’s pre-existing (potentially misinformed) framework. The framework requires that the consent discussion produce a patient understanding consistent with the actual evidence.
The framework where the patient declines recommended treatment. Where the patient, based on online information or other reasons, declines a treatment the physician recommends, the framework supports the patient’s autonomous decision. The framework also requires documentation of the discussion, including what was recommended, what the patient understood, and what the patient chose. Where the patient’s decision produces subsequent harm, the framework for liability analysis depends on whether the consent discussion met the framework’s standard.
When does harm cross into malpractice?
The framework for whether harm crosses into malpractice requires the same analysis as any other medical malpractice case: standard of care, causation, and damages.
Standard of care. Was the conduct of the physician (or other provider) consistent with what a reasonable specialist would have done in the circumstances, with expert evidence supporting the analysis? The framework operates with reference to the current professional guidelines, the specific patient’s clinical profile, and the framework’s individualized requirements.
Causation. Did the breach of the standard of care cause the harm? The framework for causation in Ontario operates on the but-for test articulated in Clements v Clements, 2012 SCC 32, with material contribution to risk available in limited circumstances. For menopause-related claims, causation typically requires showing that the patient would have made a different decision with adequate consent or assessment, and that the different decision would have produced a better outcome.
Damages. Has the patient experienced measurable harm — physical, psychological, or financial — as a consequence of the breach? The framework for damages in Ontario operates on the framework of general damages (with the rough upper limit derived from the 1978 SCC trilogy), pecuniary damages (loss of income; future care costs), and Family Law Act damages for family members.
For menopause-related care, the framework typically supports claims in several scenarios:
Failure to adequately assess. A patient presents with concerning symptoms, the framework for clinical assessment is not engaged, and a significant underlying condition (cardiovascular disease, breast cancer, osteoporosis with high fracture risk) is missed. The framework treats the failure of assessment as a breach of the standard of care, with causation depending on whether timely diagnosis would have produced a different outcome.
Failure to discuss hormone therapy as an option. A patient is a candidate for hormone therapy based on her clinical profile but the option is never discussed. The framework can support a claim where the failure produces harm (persistent severe symptoms; bone fractures attributable to untreated osteopenia; cardiovascular events in specific framings). The framework’s application is fact-specific and contested in some respects.
Inadequate informed consent for hormone therapy. A patient is prescribed hormone therapy without adequate discussion of the risks, with subsequent adverse events that the patient credibly maintains she would have avoided with adequate disclosure. The framework operates on the Reibl framework with reference to what a reasonable patient in the position of this specific patient would have wanted to know.
Prescribing outside the evidence-based framework. A physician (or non-physician practitioner) prescribes treatments that fall outside the framework of evidence-based menopause care, including compounded hormones in formulations that have not been validated, supplements with no evidence base, or other treatments. Where adverse events follow, the framework can support claims with reference to the failure to adhere to the standard of practice.
Failure to monitor. Hormone therapy and related treatments require ongoing monitoring including periodic reassessment of symptoms, side effects, breast and cardiovascular screening, and updating of the treatment plan as the patient’s clinical picture evolves. The framework supports claims where ongoing monitoring is not provided and harm follows.
The unregulated wellness industry framework
A specific dimension of the menopause information environment is the emergence of products and practitioners operating outside the conventional medical regulatory framework. The framework includes:
Compounding pharmacies and “bioidentical” hormone preparations. Some compounding pharmacies and associated practitioners market “bioidentical” hormone preparations as safer or more effective than conventional hormone therapy. The framework for these claims is contested. Some compounded preparations have not been subjected to the framework of clinical trials and regulatory review that applies to conventional pharmaceuticals. The framework for liability when adverse events arise from compounded preparations is the same framework that applies to other prescribed treatments: standard of care, informed consent, causation, and damages.
“Menopause clinics” outside conventional regulatory frameworks. Some clinics market specialized menopause care that may or may not fall within the framework of regulated medical practice. Where the practitioners are physicians regulated by the College of Physicians and Surgeons of Ontario or nurse practitioners regulated by the College of Nurses of Ontario, the framework applies in the usual way. Where the practitioners operate outside these frameworks, the framework can be different and the available remedies more limited.
Supplements and “wellness” products. Many products marketed to perimenopausal and menopausal women are sold as supplements or “wellness” products rather than as drugs. The framework for these products operates under Health Canada’s framework for natural health products, which is different from the framework for prescription drugs. Where adverse events arise from these products, the framework for liability can include product liability against the manufacturer or distributor, with separate frameworks operating from medical malpractice analysis.
Online “menopause coaches” and influencers. A significant subset of the online information environment is content produced by individuals without medical training who position themselves as experts on menopause management. The framework for liability where their advice produces harm is limited. The framework for regulatory action where they provide treatment that falls within the controlled acts framework (such as prescribing) can be more substantial, but enforcement is limited in practice.
The framework for patients in this environment is to maintain healthy skepticism, verify credentials, and engage primarily with practitioners who operate within the conventional regulatory framework. The framework for legal remedies after harm depends substantially on the regulatory status of the provider and the specific facts of the harm.
What patients can do
For patients navigating menopause and perimenopause in the current information environment, several practical observations follow from the framework.
Look for evidence-based sources. The framework for high-quality menopause information includes the Menopause Foundation of Canada, the North American Menopause Society, the Canadian Menopause Society, and similar credentialed organizations. The framework excludes most social media content, most “wellness” marketing, and most content produced by individuals without specific menopause expertise.
Bring your research to your appointments. The framework for productive engagement with the medical system includes bringing the information you have found to your appointments. Dr. Lega’s observation in the CTV News article is right: physicians should engage substantively with what patients have found rather than dismissing it. Where your physician is unwilling to engage, the framework may support seeking another opinion.
Ask about all available options. The framework for menopause care includes hormone therapy, non-hormonal pharmacotherapy, lifestyle interventions, and various combinations. The framework supports your right to a substantive discussion of each option with their respective risks and benefits.
Be skeptical of products that promise dramatic results. The framework for evidence-based menopause care produces modest, calibrated improvements in specific symptoms. The framework does not produce miraculous transformations. Marketing that promises rapid weight loss, complete symptom elimination, or other dramatic outcomes should generally be regarded with significant skepticism.
Document the discussion. Where you are considering or beginning a treatment, ask your physician to document the discussion in your chart, including what was recommended, what alternatives were considered, what risks were discussed, and what you decided. The framework for subsequent care depends on this documentation.
Speak with a lawyer if something has gone wrong. Not every adverse outcome from menopause-related care is malpractice. Emergency medicine, oncology, and similar specialties produce more catastrophic outcomes more often, and the framework for case evaluation typically focuses on those areas. But where a specific menopause-related decision has produced significant harm, the framework supports careful review of whether the standard of care was met and whether the harm is recoverable. For more on the framework for case evaluation, see Why Many Medical Malpractice Cases Are Declined in Ontario. For the framework for civil claims more broadly, see Suing for Medical Malpractice in Ontario: What You Need to Know.
A final thought
The CTV News article captures something important about the moment we are in. Information about women’s health, including menopause and perimenopause, is more widely available than ever before. The framework for evidence-based care has evolved substantially over the past two decades. The framework for shared decision-making is, in principle, better developed than it has been in generations.
The information environment, however, includes a significant volume of misinformation, marketing, and content that does not serve patients well. The framework for physicians to engage substantively with what patients are encountering is, in practice, sometimes inadequate. The framework for trust in the patient-physician relationship is, at times, eroded by the dynamic that Dr. Lega described.
The legal framework I have outlined above is the framework as it operates in Ontario today. It is calibrated to the difficulty of menopause-related care, the evolution of the evidence base, and the practical reality of the information environment. The framework supports claims where the standard of care has been breached and harm has followed. It does not support claims for every adverse outcome.
Where you have experienced significant harm in connection with menopause-related care and you believe the framework may have been breached, an early conversation with a medical malpractice lawyer can help you understand the framework’s application to your specific facts. The earlier the records can be reviewed, the better the framework for case evaluation can operate.
